In 2022, the Global Anemia Treatment Industry is anticipated to surpass US$ 10.0 billion. By 2028, the market is anticipated to be worth US$ 14.9 billion, with sales rising at a strong CAGR of 6.9%.
The majority of the demand for Anemia therapy, according to a recent report by Future Market Insights, is caused by the condition as a result of one or more chronic conditions.
Demand for Anemia treatment is largely driven by chronic kidney disease (CKD), one of the non-communicable chronic diseases responsible for the demographic shift of emerging regions. The rising popularity of combination therapy is also having a significant impact on the market for Anemia therapies. Growing usage of antibiotics, metal chelating agents, erythropoietin-stimulating drugs, and vitamin and iron supplements in combination therapy is acknowledged as a key factor boosting the outlook for the Anemia treatment market in the years to come.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-8966
Vitamin Supplements Gain Significant Traction for Anemia Treatment
A surge in R&D investments is prominently improving the scope of anemia treatment. Moreover, a rising number of pipeline drugs and the promising potential of biosimilars will contribute to the demand for anemia treatment. However, the high price point associated with biologics continues to mask their superior treatment efficacy over conventional medications.
More than 75% of anemia treatment market revenue is accounted by medications, of which, ESAs (erythropoietin stimulating agents) remain bestselling. Blood transfusion is also cited as an important type of anemia treatment, contributing to the market growth. However, the demand for the former is poised for a robust double-digit yearly growth in 2021 and ahead.
The lucrative emergence of ESAs and soaring consumption of other biosimilar medications are likely to introduce new investment opportunities in the anemia treatment market. The extensive availability, accessibility, and economic price point of biosimilar drugs are strongly backed by an increasing number of FDA approvals. This according to FMI will significantly contribute to the improvement of CKD, thereby bolstering the revenue of the anemia treatment market. FDA recently issued approval to a biosimilar drug by Pfizer for use in anemia treatment – Retacrit (epoetin alfa-epoxy).
Over 55% of dietary supplements consumed as a part of anemia treatment are vitamin supplements. An increasing number of iron-deficient patients will reportedly result in rapid demand growth for iron supplements in years to come, posing strong competition to those vitamin supplements in the anemia treatment market. Currently, almost 60% of the medications and dietary supplements for anemia treatment are available at institutional pharmacies. The report also points to a gradually expanding share of retail pharmacies shortly.
Just under a third of the global demand for anemia treatment is raised by North American patients, whereas more than a third of the total demand is accounted for collectively by East and South Asia. Europe is also cited as one of the key regional markets for anemia treatment providers.
Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-8966
Product-based Business Models Emerge as a Key Competitive Strategy
The consistent quest for therapeutically effective ESAs, dietary supplements, antibiotics, and other biologics for anemia treatment continues to create attractive avenues in the R&D realm. Leading drug manufacturers are investing efforts in launching novel products and upgrading their existing consumable product portfolios. Amgen’s epoetin alpha has been a breakthrough product since its launch in the CKD treatment landscape and growing adoption continues to benefit the company.
Besides augmenting R&D investments, prominent players in the anemia treatment market are also focusing on strategic agreements and partnerships – further paving the way for the development of anemia treatment drugs. The emergence of partnership-based models in the competitive landscape of the anemia treatment market is likely to reshape the R&D structure in the anemia treatment market. The report prompts major investment opportunities arising in open collaboration strategies. Several drug manufacturers are also opting for partnerships with regional distribution leaders to form effective product-based distribution channels, particularly targeting developing regional markets.
Anemia Treatment Market by Category
By Treatment:
- Medications
- Dietary Supplements
By Disease:
- Normocytic anemia
- Microcytic anemia
- Macrocytic anemia
By Distribution Channel:
- Institutional Pharmacies
- Retail Pharmacies
- Mail Order Pharmacies
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/8966
Key Companies Profiled:
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- AMAG Pharmaceuticals
- Rockwell Medical
- Akebia Therapeutics
- Vifor Pharma Management Ltd.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
